Chemed (CHE) Expected to Announce Earnings on Tuesday

Chemed (NYSE:CHE) is anticipated to issue its Q3 2026 results after the market closes on Tuesday, October 27th. Analysts expect the company to post earnings of $6.39 per share and revenue of $685.04 million for the quarter. Chemed has set its FY 2026 guidance at 25.000-25.750 EPS. Individuals are encouraged to explore the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Wednesday, October 28, 2026 at 10:00 AM ET.

Chemed (NYSE:CHE) last announced its quarterly earnings data on Tuesday, July 28th. The company reported $6.06 earnings per share for the quarter, beating the consensus estimate of $5.60 by $0.46. The firm had revenue of $673.25 million for the quarter, compared to analyst estimates of $665.04 million. Chemed had a net margin of 10.60% and a return on equity of 31.77%. The business’s quarterly revenue was up 8.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $4.27 earnings per share. On average, analysts expect Chemed to post $23.55 EPS for the current fiscal year and $25.17 EPS for the next fiscal year.

Chemed Price Performance

CHE stock opened at $512.72 on Monday. The company has a debt-to-equity ratio of 0.17, a current ratio of 0.91 and a quick ratio of 0.89. The company’s 50-day moving average is $514.99 and its 200-day moving average is $476.48. The stock has a market capitalization of $6.70 billion, a PE ratio of 25.75, a price-to-earnings-growth ratio of 2.06 and a beta of 0.51. Chemed has a 1 year low of $365.20 and a 1 year high of $557.00.

Chemed Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, September 3rd. Investors of record on Monday, August 17th were paid a dividend of $0.70 per share. This is an increase from Chemed’s previous quarterly dividend of $0.60. The ex-dividend date of this dividend was Monday, August 17th. This represents a $2.80 dividend on an annualized basis and a yield of 0.5%. Chemed’s dividend payout ratio (DPR) is currently 14.06%.

Insider Buying and Selling at Chemed

In other news, Director Patrick P. Grace sold 190 shares of the company’s stock in a transaction on Friday, July 31st. The shares were sold at an average price of $532.00, for a total value of $101,080.00. Following the completion of the sale, the director owned 3,533 shares in the company, valued at $1,879,556. This represents a 5.10% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Spencer S. Lee sold 1,000 shares of the company’s stock in a transaction on Friday, August 21st. The stock was sold at an average price of $541.04, for a total transaction of $541,040.00. Following the completion of the sale, the executive vice president owned 13,912 shares of the company’s stock, valued at approximately $7,526,948.48. The trade was a 6.71% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 9,190 shares of company stock worth $4,833,160. Corporate insiders own 3.33% of the company’s stock.

Wall Street Analysts Forecast Growth

CHE has been the topic of several recent research reports. Bank of America reiterated a “neutral” rating on shares of Chemed in a report on Wednesday, July 29th. Royal Bank Of Canada boosted their price objective on Chemed from $436.00 to $548.00 and gave the company a “sector perform” rating in a report on Thursday, July 30th. UBS Group initiated coverage on Chemed in a research report on Friday, September 25th. They set a “buy” rating and a $650.00 target price on the stock. Weiss Ratings raised Chemed from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, October 8th. Finally, Wall Street Zen upgraded Chemed from a “buy” rating to a “strong-buy” rating in a report on Saturday, October 10th. Two investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Chemed presently has a consensus rating of “Hold” and a consensus target price of $554.60.

About Chemed

Chemed Corporation (NYSE:CHE) is a Cincinnati, Ohio-based company that provides healthcare and residential and commercial services through two operating businesses: VITAS Healthcare and Roto-Rooter. Its operations serve customers primarily in the United States, with Roto-Rooter also providing services in Canada.

VITAS Healthcare is a provider of hospice and palliative care for individuals with advanced illnesses. The business delivers care in patients’ homes, hospice inpatient units, hospitals, nursing facilities and other care settings.